Market News / Story
Bluejay Diagnostics reports SYMON-II dataset: 777 patients, ~18% 28-day mortality for IL-6 evaluation
·
Bluejay Diagnostics announced baseline SYMON-II data showing 777 evaluable patients and an ~18% 28-day mortality rate to support IL-6 prognostic evaluation. Key Highlights: SYMON-II preliminary dataset includes 777 evaluable patients (637 survivors, 140 non-survivors). Overall 28-day mortality approximately 18%, providing meaningful outcome events for biomarker analysis. 39.5% of patients met Sepsis-3 criteria for septic shock; non-survivors had higher shock rates…